{"id":210678,"date":"2023-12-20T00:00:00","date_gmt":"2023-12-20T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/47041149-medtech-peripheral-vascular-devices-market-insights\/"},"modified":"2026-03-31T10:11:49","modified_gmt":"2026-03-31T10:11:49","slug":"47041149-medtech-peripheral-vascular-devices-market-insights-europe-part-2","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47041149-medtech-peripheral-vascular-devices-market-insights-europe-part-2\/","title":{"rendered":"Peripheral Vascular Devices &#8211; Market Insights &#8211; Europe Part 2"},"content":{"rendered":"<p>The European <abbr title=\"Peripheral Vascular\">PV<\/abbr> device will grow <span>modestly<\/span> through 2032. Market expansion will be driven by an increasing <abbr title=\"Peripheral Artery Disease\">PAD<\/abbr> patient pool, adoption of drug-eluting technologies, and a <span>rising preference<\/span> for the endovascular approach over open surgery; however, declining <abbr title=\"Average Selling Price\">ASP<\/abbr>s and <span>rising pricing<\/span> competition will somewhat restrict revenue growth.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the state of the market for <abbr title=\"Peripheral Vascular\">PV<\/abbr> devices in Europe from 2019 through 2032.<\/p>\n<p><strong>Drug-eluting technologies and <span>favorable<\/span> reimbursement in countries like Belgium for endovascular procedures will drive growth of these devices.<\/strong><\/p>\n<p>How will the latest <abbr title=\"Food and Drug Administration\">FDA<\/abbr> guidelines on the use of paclitaxel-coated devices affect the European market?<\/p>\n<p>To what degree will <abbr title=\"Drug-Eluting Stent(s)\">DES<\/abbr> and <abbr title=\"Drug-Coated Balloon\">DCB<\/abbr>s be adopted in covered geographies over the forecast period?<\/p>\n<p>How will the adoption of <abbr title=\"Drug-Eluting Stent(s)\">DES<\/abbr> and <abbr title=\"Drug-Coated Balloon\">DCB<\/abbr>s impact the competitive landscape?<\/p>\n<p><b>Developments in endovascular interventions are focusing on treating the lower extremities.<\/b><\/p>\n<p>How has the expanded indication for endovascular interventions impacted the <abbr title=\"Peripheral Vascular\">PV<\/abbr> device market?<\/p>\n<p>What new products are going to be available in the market, and how will they change the competitive landscape?<\/p>\n<p>Will <abbr title=\"Drug-Coated Balloon\">DCB<\/abbr>s or <abbr title=\"Drug-Eluting Stent(s)\">DES<\/abbr> become the first line of solution for <abbr title=\"Below-the-Knee\">BTK<\/abbr> lesions?<\/p>\n<p><b>Mergers and acquisitions involving big competitors will lead to shifts in the market going forward.<\/b><\/p>\n<p>What acquisitions have occurred to allow companies to better position themselves to enter the <abbr title=\"Drug-Coated Balloon\">DCB<\/abbr>, percutaneous thrombectomy device, or atherectomy device markets?<\/p>\n<p>How are competitors leveraging company and product portfolio acquisitions to expand their product offerings?<\/p>\n<p><strong>Budgetary constraints and insufficient reimbursement in some segments continue to affect the European <abbr title=\"Peripheral Vascular\">PV<\/abbr> device market.<\/strong><\/p>\n<p>To what extent will the lack of reimbursement affect the adoption of premium-priced devices like lithotripsy balloons and intravascular ultrasound?<\/p>\n<p>How fast will <abbr title=\"Average Selling Price\">ASP<\/abbr>s erode and which countries will experience the greatest erosion?<\/p>\n<p>What strategies are the competitors adopting to navigate the challenging cost-constrained European <abbr title=\"Peripheral Vascular\">PV<\/abbr> device market?<\/p>\n","protected":false},"template":"","class_list":["post-210678","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-cardiovascular","medtech-therapy-area-peripheral-vascular-devices","medtech-geography-europe","medtech-date-976"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/210678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/210678\/revisions"}],"predecessor-version":[{"id":281358,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/210678\/revisions\/281358"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=210678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}